Ruth Riisnaes

6PUBLICATIONS
146CO-AUTHORS
Tumour immunologyMolecular targetsPredictive and prognostic markersCancer therapy (excl. chemotherapy and radiation therapy)
Featured researcher

Get your video featured.

JoVEPublish with JoVE
Journal

Publications (6)

|Apr 27, 2026
Phase I Trial of Ipatasertib plus Atezolizumab Enhances PI3K/AKT Pathway Immune Responses in Solid Tumors and Refractory Glioblastoma.

|Jan 09, 2025
NXP800 Activates the Unfolded Protein Response, Altering AR and E2F Function to Impact Castration-Resistant Prostate Cancer Growth.

Jonathan Welti, Denisa Bogdan, Ines Figueiredo

|Feb 27, 2024
Thio-2 Inhibits Key Signaling Pathways Required for the Development and Progression of Castration-resistant Prostate Cancer.

Antje Neeb, Ines Figueiredo, Denisa Bogdan

|Sep 29, 2023
Olaparib and Ceralasertib (AZD6738) in Patients with Triple-Negative Advanced Breast Cancer: Results from Cohort E of the plasmaMATCH Trial (CRUK/15/010).

Alistair Ring, Lucy S Kilburn, Alex Pearson

|Oct 23, 2022
SMG8/SMG9 Heterodimer Loss Modulates SMG1 Kinase to Drive ATR Inhibitor Resistance.

Marta J Llorca-Cardenosa, Lauren I Aronson, Dragomir B Krastev

|Aug 19, 2022
A Phase I Trial of CT900, a Novel α-Folate Receptor-Mediated Thymidylate Synthase Inhibitor, in Patients with Solid Tumors with Expansion Cohorts in Patients with High-Grade Serous Ovarian Cancer.

Susana Banerjee, Vasiliki Michalarea, Joo Ern Ang

Pageof 1

Frequent Collaborators

6 joint publications

Bora Gurel

5 joint publications

Ana Ferreira

5 joint publications

Johann S de Bono

3 joint publications

Wei Yuan